Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Loxo Oncology Inc.

Division of Eli Lilly & Co.
www.loxooncology.com

Latest From Loxo Oncology Inc.

Lilly Taps Loxo Execs To Bring Back That Biotech Feeling

Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.

ImmunoOncology Research & Development

Lilly’s Diabetes Franchise Poised For A Shakeup As Conterno Steps Down

Lilly’s newer diabetes drugs are selling well, although Trulicity numbers disappointed analysts, and are among the firm’s growth-drivers. Longtime diabetes head Enrique Conterno will be succeeded by insider Mike Mason.

Sales & Earnings Business Strategies

Lilly’s Pegilodecakin Fails Pancreatic Cancer Test

The company's immunotherapy failed to improve survival of pancreatic patients compared to chemotherapy. Lilly will be hoping pegilodecakin has more success in NSCLC.

Clinical Trials ImmunoOncology

Pharma Will Embrace Basket And Umbrella Trials, Despite Challenges

New approaches in study design and methodology, including master protocol trials, are being adopted by biopharma.
Clinical Trials FDA
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Eli Lilly & Co.
  • Senior Management
  • Joshua H Bilenker, MD, Pres. & CEO
    Nisha Nanda, PhD, Chief Dev. Officer
    Jennifer Burstein, SVP, Fin.
    Jacob Van Naarden, COO
  • Contact Info
  • Loxo Oncology Inc.
    Phone: (203) 653-3880
    281 Tresser Blvd.
    9th Floor
    Stamford, CT 06901
    USA
UsernamePublicRestriction

Register